ClinicalTrials.gg
RecruitingNCT06033014PM HeartUpdated Jan 22, 2024

Clinical Implementation of a Novel Decision Support Tool in Patients With Ischemic Heart Disease

An interventional study of PM HeartIHD prediction in Ischemic Heart Disease, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark — 3 open to participants now, 3 under way, none of them phase 3. Myocardial Ischemia · Rigshospitalet, Denmark.

Planned enrollment
Largest of 12
8,000 · median 54
Started
2023
with 1 other
No phase
5 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 with no phase, and was the 12th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

3 of the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

The PM-Heart algorithm (PMHeartIHD) is an in-house developed software that predict the survival prognosis for the individual patient hospitalized with ischemic heart disease (IHD) after a coronary arteriography has been performed. The software is intended to be used as a clinical decision support system i.e. the calculated survival prognosis is expected to enhance the quality of the treating physician's therapeutic considerations concerning (minor) adjustments to the patients treatment and follow-up - all within the framework of the current medical guidelines. Thus, the algorithm does not "show the physician specifically what to do", but rather ensures a better knowledgebase for the overall interpretation and choice of management of the patient.

Read the detailed description

To investigate the clinical usefulness of the developed clinical decision support system - the PMHeartIHD algorithm - we wish to investigate whether the clinical use of the algorithm will;

  • Improve patient prognosis and,
  • Minimize the risk of re-hospitalization,

compared to patients who are treated without the attending/treating physician knowing the algorithm's prognosis?

03

Conditions studied

  • Ischemic Heart Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients in one of the involved departments of cardiology (see below) with;
  • Ischemic heart disease; the clinical presentation may be stable, worsening/unstable angina, non-ST-elevation myocardial infarction or ST-elevation myocardial infarction, and with - Significant coronary artery lesions or diffuse coronary artery disease on invasive coronary angiography during the admission

Exclusion criteria

Exclusion Criteria:

  • \<18 years of age
  • Living outside Denmark
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,000 participants (estimated)

Study arms

  • No intervention
    Control

    The one-year mortality prediction, calculated by the PM Heart algorithm, will not be available to the physician.

  • Experimental
    Intervention

    The one-year mortality prediction, calculated by the PM Heart algorithm, will be available to the physician.

    Other: PM HeartIHD prediction

Interventions

  • OtherPM HeartIHD prediction

    The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.

06

What researchers measure

Primary outcomes

  1. Number and duration of readmissions within one month after randomization

    A composite outcome of a) readmissions within one month, and 2) all-cause mortality within one year - for patients randomized to the study. All the outcomes listed below will be assessed as a comparison between the "intervention group" and the "control group".

    Time frame: From randomization to the study and up to 1 year hereafter

  2. Number and cause of death (all-cause mortality) within one year after randomization

    A composite outcome of a) readmissions within one month, and 2) all-cause mortality within one year - for patients randomized to the study.

    Time frame: From randomization to the study and up to 1 year hereafter

Secondary outcomes

  1. Readmission(s) within 30 days of the randomization

    Readmission(s) within 30 days of the randomization. Incl. information on the quantity, duration, cause, outcome etc.

    Time frame: Up to 30 days after randomization to the study.

  2. Cardiovascular readmission(s) within 30 days of the randomization

    Cardiovascular readmission(s) within 30 days of the randomization. Incl. information on the quantity, duration, cause, outcome etc.

    Time frame: Up to 30 days after randomization to the study.

  3. Readmission(s) with acute coronary syndrome

    Readmission(s) with acute coronary syndrome. Incl. information on the quantity, duration, cause, outcome etc.

    Time frame: From randomization to the study and up to 1 year hereafter

  4. One-year survival

    One-year survival

    Time frame: From randomization to the study and up to 1 year hereafter

  5. Total number of days the primary hospitalization lasts

    Length (i.e. total number of days) of the primary hospitalization (i.e. when the patient is randomized to the study).

    Time frame: From randomization to the study and up to 1 year hereafter

  6. Total number of days at the hospital incl. hospitalizations during the first year after inclusion

    Total number of days in hospital during the first year after inclusion

    Time frame: From randomization to the study and up to 1 year hereafter

  7. Number of hospitalizations the first year

    Number of hospitalizations the first year

    Time frame: From randomization to the study and up to 1 year hereafter

  8. Number and type of performed cardiac investigations

    Number and type of performed cardiac investigations; i.e. TTE, KAG, Heart-CT, Holter/R-tests, ECG, blood samples, etc.

    Time frame: From randomization to the study and up to 1 year hereafter

  9. Number of cardiac follow-up consultations at the hospital

    Number of cardiac follow-up consultations at the hospital

    Time frame: From randomization to the study and up to 1 year hereafter

  10. Number of check-ups for cardiovascular reasons at the general practitioner

    Number of check-ups for cardiovascular reasons at the general practitioner.

    Time frame: From randomization to the study and up to 1 year hereafter

  11. Number of cardiovascular drugs at discharge

    Number of cardiovascular drugs at discharge + after 1 year.

    Time frame: From randomization to the study and up to 1 year hereafter

  12. Dosages (DDD) of drugs at discharge

    Dosages (DDD) of drugs at discharge + after 1 year.

    Time frame: Up to 1 year after randomization to study.

  13. Incidence of a) new ischemic events, b) arrhythmias, c) and/or heart failure

    Incidence of a) new ischemic events, b) arrhythmias, c) and/or heart failure

    Time frame: Up to 1 year after randomization to study.

  14. Health economic analyses of implementing the algorithm

    Health economic analyses: How does implementing the algorithm alter the overall costs and resource spending, incl. e.g. social benefits, compared with standard-of-care. i.e. does knowing a more precise 1-year mortality prediction reduce/increase the resource consumption. Will be based on economic analyses of the costs related to the abovementioned outcome measurements.

    Time frame: Up to 1 year after randomization to study.

  15. The algorithm's reception and introduction in clinical use

    We wish to investigate how the algorithm is introduced and received in the clinic, both by the medical staff but also the patients. Will be investigated using interviews.

    Time frame: Before start of clinical study and up to 1 year after randomization to study.

  16. The usability of the algorithm

    The usability of the algorithm i.e. is it easy to use/understand, any praise or criticisms, ideas for new features etc. Will be based on questionaires and feedback from users.

    Time frame: Before start of clinical study and up to 1 year after randomization to study.

  17. How, and to what extend, is the algorithm used by the medical staff.

    We wish to investigate how, and to what extend, the algorithm is used by the medical staff, e.g. are the medical staff inclined to use the prediction, does it alter their treatment choices etc. Will be based on questionaires, interviews, feedback from users, and assessment of "look-ups".

    Time frame: Before start of clinical study and up to 1 year after randomization to study.

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital.
    Copenhagen Ø, 2100, Denmark
    Recruiting
    • Henning Bundgaard, MD, DMSci · Contacthenningbundgaard@dadlnet.dk · +4535450512
    • Henning Bundgaard, MD, PhD, DMSc · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 39 months is above that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Sep 13, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06033014
Collaborators
Region Capital Denmark, Region Zealand
Responsible party
Henning Bundgaard (Professor of Cardiology, Consultant, MD, DMSc, Rigshospitalet, Denmark) — Principal investigator
First posted
Sep 13, 2023
Start date
Sep 18, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 22, 2024

Study contacts

Henning Bundgaard, Professor
Contact
henning.bundgaard@regionh.dk
+4535450512

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion